Research Focus

Former Employee. Medicine; Research Stdy Asst II

Recent additions – View all

1. A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)

   Meeting Abstract

   Johnson, M. L.; Hart, E. M.; Rademaker, A.; Weitner, B. B.; Urman, A.; Simm, H. D.; Fountas, L. M.; Worden, R.; Patel, J. D.; Miller, V. A.; more...
   Journal of Clinical Oncology (2013)

   Fulltext@MSK | Save
2. A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS)

   Meeting Abstract

   Yu, H. A.; Johnson, M. L.; Urman, A.; Rademaker, A.; Hart, E.; Weitner, B. B.; Patel, J. D.; Kris, M.; Riely, G.
   Journal of Thoracic Oncology (2013)

   Fulltext@MSK | Save